Skip to main content
OpenTrials
Completed

NCT Number: NCT05566730

Culturally Tailored Cannabis Use Disorder App

The present study aims to address disparities in cannabis use outcomes among African American/Black (hereby referred to as Black) adults with cannabis use disorder (CUD). The specific aims of this study are: (1) to develop a culturally adapted, mobile app for Black cannabis users (CT-MICART) using knowledge from the current research team, published literature, expert opinion, and feedback from the Community Research Advisory Board (CRAB), (2) to pilot test CT-MICART and (3) focus on analysis of data collected as part of Aim 2.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Houston

Houston, Texas, 77004, United States

About this study

The present study aims to address disparities in cannabis use outcomes among African American/Black (hereby referred to as Black) adults with cannabis use disorder (CUD). African American/Black adults are more likely to endorse cannabis use patterns that are more severe (weekly and blunt use) and meet diagnostic criteria for cannabis use disorder (CUD) than White adults (16.8% vs 10.0%). This finding is alarming as cannabis use disorder is associated with more severe psychosocial risk profiles, including poly-substance use, psychiatric problems, and legal trouble relative to non-CUD use and non-use. Additionally, although Black cannabis users are more likely to report being ready to quit and a recent quit attempt relative to White cannabis users, this population is less likely to seek in-person treatment relative to White cannabis users because of individual (e.g., beliefs about use), community (e.g., neighborhood attitudes about use), and institutional (e.g., healthcare access) factors as well as due to institutionalized racism and discrimination (e.g., more likely to not be listened to by practitioners). Targeted, accessible, and culturally adapted therapeutic programming is needed to reduce risk and improve disparities for poor cannabis-related outcomes among Black adults with cannabis use disorder. These findings are significant because they contribute to heath, social, and psychological health disparities within the Black community. Psycho-sociocultural models of substance use posit that Black individuals may use cannabis and continue using despite cannabis-related problems including cannabis use disorder, to manage psychological distress associated with stressors associated with minority status, such as racial discrimination. Therefore, the present study seeks to develop a culturally adapted, mobile app tailored specifically for Black cannabis users (CT-MICART). Using the expert opinion and feedback from the community Research Advisory Board (CRAB), the investigative team will pilot test CT-MICART and focus on analysis of data collected to help achieve a better culturally tailored app.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • at least 18 years of age
  • identify as Black/African American
  • CUD per CUPIT-R
  • willing and able to complete study appointments
  • motivated to reduce cannabis (≥5 on a 10-point scale)
  • score ≥ 4 on the REALM-SF indicating ≥ 6th grade English literacy level (needed to use app)
  • report cannabis use to manage anxiety/stress in the past month

Exclusion criteria

  • legal mandate or substance misuse treatment
  • report of current or intended participation in a concurrent substance use treatment, including pharmacotherapy or psychotherapy for CUD not provided by researchers
  • ongoing psychotherapy of any duration directed specifically toward the treatment of anxiety or depression
  • not being fluent in English
  • pregnant of planning to become pregnant within the next six months (assessed via self-report)

Treatment and study plan

CT-MICART App

Behavioral

App designed with the goal of treating CUD in African American adults

Control

Behavioral

App designed with the goal of treating CUD in African American adults, with participants just tracking their use of cannabis and not receiving treatment videos

Other names: Sham

Primary outcomes

  1. Safety Aid Scale

    Time frame: Baseline appointment and 6-week follow up appointment

    The Safety Aid Scale will be used to assess change of false safety behavior use over time, being scored on a 5 point scale where higher scores indicate greater use of false safety behaviors.

  2. Qualitative Interview

    Time frame: 6-week follow up appointment

    The qualitative interview done by the participants will ask them about their experience with the app, what aspects helped, what aspects didn't help, and will allow researchers to adapt and refine the CT-MICART app.

  3. Engagement with the CT-MICART app

    Time frame: Week 1-6

    Behavioral indicators of engagement with the app (>75% of all videos watched and >75% of scheduled skills practiced).

Sponsors and collaborators

Lead sponsor

University of Houston

Other

Collaborators

  • Louisiana State University Health Sciences Center in New Orleans
  • National Institute on Minority Health and Health Disparities (NIMHD)
  • University of Oklahoma

Registry information

Official study title

Mobile App to Address CUD Among Black Adults

Important dates

Study start
2023
Primary completion
2023
Study completion
2024
First posted
Oct 4, 2022
Registry last updated
May 7, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.